Why United Health $UnitedHealth(UNH)$
πππ It is hard to watch a giant bleed. For years, United Health was the untouchable fortress of healthcare, a too big to fail colossus, a sleep well at night blue chip stock.
Then 2025 happened.
A stunning brutal reversal. Unprecedented selling pressure, a high profile leadership change and a 20% drop in just one month in early 2026 left long term holders shell shocked. The narrative was filled with negativity : DOJ investigations, Medicare Advantage rate squeezes and the pain of right sizing through the loss of over a million members. It felt like a company crumbling under the weight of its own ambition.
But here is the turnaround :
The Q1 2026 earnings report, released on April 21 didn't just beat expectations. It signaled a fundamental turning point.
The narrative has shifted from "How much will they lose?" to "How fast will they grow?"
Q1 2026 Earnings : The Turnaround in Numbers
Massive Double Beat: UNH reported adjusted earnings of USD 7.23 per share, crushing the USD 6.57 Wall Street expected.
Revenue hit USD 111.72 billion, proving that despite the right sizing, UNH's engine is still roaring.
The MCR Victory: The most critical metric - the Medical Care Ratio (MCR) has improved to 83.9% down from 84.8% a year ago. This means that UNH is managing medical costs better than skeptics fear.
Guidance Hike: Management raised the full year 2026 adjusted EPS outlook to at least USD 18.25, a significant jump from their previous floor of USD 17.75.
The Dividend: Your Paycheck to Wait
While you wait for the recovery to complete, UNH remains a "dividend contender" with a bulletproof payout.
Forward Yield - 2.50%, currently sitting around 79% above its 10 year median, signalling a massive historical value opportunity.
Safety : A sustainable 48% payout ratio leaves plenty of room for their 15 year streak of increases to continue.
Technical Outlook :The USD 350 Support
The New Floor: The USD 350 mark has transitioned from a psychological barrier to a critical support zone.
Bullish Breakout : UNH surged over 8% following the report, reclaiming key moving averages. Analysts from Argus, Morgan Stanley and Oppenheimer have recently raised their targets to the USD 395 to 405 range.
Buyback Signal : UNH plans to repurchase at least USD 2 billion in stock by the end of Q2, putting a floor under the price.
Concluding Thoughts
For a patient long term investor, UNH offers a compelling combination of a solid dividend profile and a significant share price upside as margins recover over the next 12 to 18 months. This makes UNH a high quality, undervalued blue chip stock within the healthcare sector.
@Tiger_comments @TigerStars @TigerClub @Tiger_SG @CaptainTiger
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- vippyΒ·04-27 17:03TOPUNH looks solid for a rebound play.1Report
- Brando741319Β·00:27Good1Report